ZYNE Zynerba Pharmaceuticals Inc

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Okta, Inc. (NASDAQ:OKTA), Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), BioXcel Therapeutics, Inc. (NASDAQ:BTAI), Capital Southwest Corporation (NASDAQ:CSWC), Amber Road, Inc. (NYSE:AMBR), and Foundation Building Materials, Inc. (NYSE:FBM), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

OKTA DOWNLOAD: http://Capital-Review.com/register/?so=OKTA ZYNE DOWNLOAD: http://Capital-Review.com/register/?so=ZYNE BTAI DOWNLOAD: http://Capital-Review.com/register/?so=BTAI CSWC DOWNLOAD: http://Capital-Review.com/register/?so=CSWC AMBR DOWNLOAD: http://Capital-Review.com/register/?so=AMBR FBM DOWNLOAD: http://Capital-Review.com/register/?so=FBM

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Capital Review, available for free download at the links above, examine Okta, Inc. (NASDAQ:OKTA), Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), BioXcel Therapeutics, Inc. (NASDAQ:BTAI), Capital Southwest Corporation (NASDAQ:CSWC), Amber Road, Inc. (NYSE:AMBR), and Foundation Building Materials, Inc. (NYSE:FBM) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

OKTA, INC. (OKTA) REPORT OVERVIEW

Okta's Recent Financial Performance

For the three months ended January 31st, 2019 vs January 31st, 2018, Okta reported revenue of $115.47MM vs $77.05MM (up 49.86%) and analysts estimated basic earnings per share -$0.28 vs $0.01. For the twelve months ended January 31st, 2019 vs January 31st, 2018, Okta reported revenue of $399.25MM vs $256.55MM (up 55.63%) and analysts estimated basic earnings per share -$1.17 vs -$1.32. Analysts expect earnings to be released on June 5th, 2019. The report will be for the fiscal period ending April 30th, 2019. The reported EPS for the same quarter last year was -$0.23. The estimated EPS forecast for the next fiscal year is -$1.16 and is expected to report on March 5th, 2020.

To read the full Okta, Inc. (OKTA) report, download it here: http://Capital-Review.com/register/?so=OKTA

-----------------------------------------

ZYNERBA PHARMACEUTICALS, INC. (ZYNE) REPORT OVERVIEW

Zynerba Pharmaceuticals' Recent Financial Performance

Analysts expect earnings to be released on May 14th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was -$0.91. The estimated EPS forecast for the next fiscal year is -$2.05 and is expected to report on March 9th, 2020.

To read the full Zynerba Pharmaceuticals, Inc. (ZYNE) report, download it here: http://Capital-Review.com/register/?so=ZYNE

-----------------------------------------

BIOXCEL THERAPEUTICS, INC. (BTAI) REPORT OVERVIEW

BioXcel Therapeutics' Recent Financial Performance

Analysts expect earnings to be released on May 13th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was -$0.37. The estimated EPS forecast for the next fiscal year is -$3.01 and is expected to report on March 5th, 2020.

To read the full BioXcel Therapeutics, Inc. (BTAI) report, download it here: http://Capital-Review.com/register/?so=BTAI

-----------------------------------------

CAPITAL SOUTHWEST CORPORATION (CSWC) REPORT OVERVIEW

Capital Southwest's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Capital Southwest reported revenue of $13.87MM vs $9.02MM (up 53.80%) and basic earnings per share $0.25 vs $0.64 (down 60.94%). For the twelve months ended March 31st, 2018 vs March 31st, 2017, Capital Southwest reported revenue of $35.13MM vs $23.47MM (up 49.64%) and analysts estimated basic earnings per share $2.45 vs $1.48 (up 65.54%). Analysts expect earnings to be released on June 3rd, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.26. The estimated EPS forecast for the next fiscal year is $1.70 and is expected to report on June 3rd, 2019.

To read the full Capital Southwest Corporation (CSWC) report, download it here: http://Capital-Review.com/register/?so=CSWC

-----------------------------------------

AMBER ROAD, INC. (AMBR) REPORT OVERVIEW

Amber Road's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Amber Road reported revenue of $21.88MM vs $20.63MM (up 6.06%) and analysts estimated basic earnings per share -$0.20 vs -$0.07. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Amber Road reported revenue of $85.17MM vs $79.08MM (up 7.70%) and analysts estimated basic earnings per share -$0.49 vs -$0.47. Analysts expect earnings to be released on May 9th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.11. The estimated EPS forecast for the next fiscal year is -$0.23 and is expected to report on February 10th, 2020.

To read the full Amber Road, Inc. (AMBR) report, download it here: http://Capital-Review.com/register/?so=AMBR

-----------------------------------------

FOUNDATION BUILDING MATERIALS, INC. (FBM) REPORT OVERVIEW

Foundation Building Materials' Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Foundation Building Materials reported revenue of $360.77MM vs $313.54MM (up 15.06%) and analysts estimated basic earnings per share $0.42 vs $1.82 (down 76.92%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, Foundation Building Materials reported revenue of $2,044.31MM vs $1,790.11MM (up 14.20%) and analysts estimated basic earnings per share -$0.28 vs $1.99. Analysts expect earnings to be released on May 8th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.01. The estimated EPS forecast for the next fiscal year is $1.10 and is expected to report on February 24th, 2020.

To read the full Foundation Building Materials, Inc. (FBM) report, download it here: http://Capital-Review.com/register/?so=FBM

-----------------------------------------

ABOUT CAPITAL REVIEW

Capital Review is a nationally recognized publisher of financial analysis, research reports, and exclusive market reporting. Institutional investors, registered brokers, professional traders, and personal investment advisers rely on Capital Review to quantify public company valuations, discover opportunity across asset classes, stay informed about market-moving events, and read exclusive analysis of important material developments. With 14 offices worldwide, Capital Review staffs and manages certified and registered financial professionals, including Chartered Financial Analyst® (CFA®) designation holders and FINRA® BrokerCheck® certified individuals with current and valid CRD® number designations, to enable continuous coverage of topics relevant to its regular active reader base.

REGISTERED MEMBER STATUS

Capital Review's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Capital Review's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Capital Review have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Capital Review's Compliance department by Phone, at +1 (410) 280-7496, or by E-mail at compliance@Capital-Review.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Capital Review, Capital Review members, and/or Capital Review affiliates are not responsible for any gains or losses that result from the opinions expressed. Capital Review makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Capital Review has not been compensated for the publication of this press release by any of the above mentioned companies. Capital Review is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact: Morena Zambada, Media Department Office: +1 (410) 280-7496 E-mail: media@Capital-Review.com

© 2019 Capital Review. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Capital-Review.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.